[Probe (1980): (XX), 1, 13-17]
Geriforte in Neurological Disorders
Velmurugendran, C.U., M.D., D.M. (Neurology),
Professor and Neurologist
Virudhagirinatha, B.S., M.A.,
Department of Medical Neurology,
Stanley Medical College and Government Stanley Hospital, Madras, India.
The physical and mental fitness of an individual depends largely on healthy tissues, which in turn
are responsible for proper physiological functioning. Geriforte is reported to improve the sense of
well-being by promoting a feeling of physical energy and mental competence for performing
Geriforte is reported to arrest degenerative changes and accelerate cellular regeneration and repair
and also to improve hormone utilization. It tones up the heart, improves circulation, and reduces
levels of serum cholesterol and other lipids. It increases physical capacity, raises the threshold of
fatiguability, improves mental acuity and activates the nervous system.
The adaptogenic properties of Geriforte induce better stress tolerance by correcting the level of
neurohumours, improve the endocrine function and protein metabolism. In the present study, the
clinical effects on the endocrine, neurohumoral and metabolic function will be studied by
administering Geriforte, an indigenous compound containing various reputed ingredients having
various reconstituents, tonics and hepatic stimulants.
Each Geriforte tablet contains:
Chyavanprash concentrate 100 mg
Exts. Capparis spinosa 13.8 mg
Cichorium intybus 13.8 mg
Solanum nigrum 6.4 mg
Cassia occidentalis 3.2 mg
Terminalia arjuna 6.4 mg
Achillea millefolium 3.2 mg
Tamarix gallica 3.2 mg
Mandur bhasma 5 mg
Saffron 5 mg
Amber 2 mg
Makardhwaj 10 mg
Asparagus adscendens 10 mg
Caesalpinia digyna 10 mg
Asparagus racemosus 20 mg
Withania somnifera 30 mg
Glycyrrhiza glabra 20 mg
Centella asiatica 20 mg
Shilajeet (Purified) 20 mg
Terminalia chebula 15 mg
Mucuna pruriens 10 mg
Myristica fragrans 10 mg
Piper longum 10 mg
Mace 10 mg
Eugenia caryophyllata 5 mg
Elettaria cardamomum 5 mg
Carum copticum 5 mg
Curcuma longa 5 mg
Exts. Berberis aristata 10 mg
Adhatoda vasica 10 mg
Eclipta alba 10 mg
Celastrus paniculatus 5 mg
Argyreia speciosa 10 mg
Abhrak bhasma 10 mg
Loh bhasma 5 mg
Jasad bhasma 10 mg
Processed in Phyllanthus emblica, Terminalia chebula, Eclipta alba, Asparagus racemosus, Allium
cepa, Allium sativum, Phyllanthus niruri, Boerhaavia diffusa, Tinospora, cordifolia, Berberis
aristata, Raphanus sativus, Tribulus terrestris, Dashamoola.
As Geriforte enhances mental acuity of the individual and improves the general health, it has been
chosen for clinical study.
MATERIAL AND METHODS
Seventy patients were selected from the Department of Medical Neurology, Stanley Medical
College and Government Stanley Hospital, Madras. They were divided into the following four
Group I : Cases with pure cerebroneurological lesion.
Group II : Cases with peripheral lesion.
Group III: Cases with minimal symptoms.
Group IV: Cases with dementia.
Table I: Age distribution in each group
No. of cases in each group
Age in years
I II III IV
10-15 3 – 3 –
16-20 6 1 5 2
21-30 6 – 8 4
31-40 7 2 – 2
41-50 1 – 3 2
51-60 3 – 1 6
Over 61 – 1 4 –
Total 26 4 24 16
Group I consisted of patients who had cerebral lesions such as epilepsy, meningitis, stroke,
degenerative disease, mental retardation and extrapyramidal disorder.
Group II consisted of patients who had lesions such as peripheral neuritis, anterior horn cell
Group III consisted of patients who had symptoms like headache, loss of memory, inability to
concentrate etc. This Group also included apparently normal persons and others who volunteered
for enhancing their mental capability.
Group IV consisted of those with dementia and were being treated at the mental hospital.
There were 26 cases in Group I, 4 cases in Group II, 24 cases in Group III and remaining 16 were in
Group IV. The age group of the patients was 10 to 70 years.
Groups I, II and III were examined completely, a thorough neurological examination was made.
Appropriate investigations such as blood examinations, skull X-rays, EEG and EMG studies were
also carried out. They were tested by a competent neuro-psychologist and they were assessed for the
following neuro-psychological functions namely (1) attention and concentration (2) memory (3)
intelligence (4) immediate memory (5) retention (6) visuomotor co-ordination and visual recalls.
Attention and concentration were assessed by the Knox-Cuba Test. Intelligence was measured by
Bhatia's battery of performance tests of intelligence (Short Scale). Memory was evaluated by
Wechsley Memory Scale Form I. Perceptomotor function was assessed by Bender Visual Motor
Gestalt Test. All these are standardised tests. Personality tests such as Rorschach Ink-Blot Test and
Eysenck Personality Inventory were given to six patients who had personality problems.
Neuropsychological changes in the mild group were observed for a period of one year in these
Table II: Pure neurological deficit group – initial findings
Symptoms Normal Below normal
Attention and concentration 1 24
Memory 2 23
Immediate memory 2 24
Retention 1 24
Intelligence 6 19
Visuomotor concentration 13 10
Visual recall 5 18
Pure Neurological Deficit Group
In the pure neurological deficit group, Group I there were 26 cases. Two patients could not be tested
due to hemiplegia.
They were followed-up for one month, three months and six months. Eight patients were subjected
to psychological testing at the end of one and three months, and six at the end of 6 months.
Attention and concentration improved in 2 at the end of one month, in one at the end of 3 months
and three out of 6 at the end of six months. Memory improved in one case at the end of one month,
three at the end of three months and three out of six in six months. Regarding immediate memory,
one case improved at the end of one month, three at the end of three months and four out of six at
the end of six months. In one patient, retention was found improved at the end of three months and
six months. Intelligence improved in one case at the end of one month and in another case at the end
of six months. Visuomotor co-ordination improved in one case at the end of one month, in two
cases at the end of three months and in four cases out of six at the end of six months. Visual recall
improved in two cases each at the end of one month, three months and six months. Some cases
remained unchanged but none deteriorated at the end of one month, three months and six months on
Peripheral Lesion Group
Four cases came under Group II for study of neuropsychological changes in the peripheral type of
disease. All of them exhibited abnormality in attention and concentration, immediate memory,
intelligence and visual recall. The next affected function was memory. The next affected function
was memory. Two patients reported for review at the end of one month. Memory, visual recall and
retention were found improved. The rest of the functions remained unchanged. One patient of
peripheral neuropathy and pain showed improvement at the end of three months. Even though the
sample is small, the results on follow-up are decidedly very encouraging.
Table III: Initial examination – minimal symptom group
Psychological function Normal % Below Normal %
Attention and concentration – – 24 (100.0)
Memory 18 (75) 6 (25.0)
Immediate memory 13 (54.2) 11 (45.8)
Retention 6 (25) 18 (75.0)
Intelligence 14 (58.3) 10 (41.7)
Visuomotor concentration 22 (91.2) 2 ( 8.8)
Visual recall 7 (29.2) 17 (70.8)
Minimal Symptom Group
In Group III, the minimal symptom group, the neuropsychological changes were as follows:
At the initial assessment, all the 24 cases exhibited below normal level of attention and
concentration. The next most disturbed functions were retention and visual recall. Subnormal
memory and intellectual level were seen in 11 and 10 cases respectively. The least affected function
was visuomotor co-ordination.
Fourteen patients reported for follow-up at the end of one month. 9 patients showed improvement in
attention and concentration; five cases exhibited improvement in immediate memory and retention
capacity. Visual recall improved in 3 cases, memory in 2 cases and visuomotor co-ordination in one
case. None of the patients showed deterioration.
Seven patients reported for the third monthly follow-up testing. Improvement in immediate memory
was seen in all the seven cases, improvement in attention and concentration in six cases, visual
recall in 5 cases and improvement in retention and intelligence in 4 cases. Immediate memory and
retention and concentration were recovered fully. None showed deterioration.
Five patients reported at the end of six months. All of them showed improvement in attention and
concentration. Improvement in memory and visual recall improved in four cases, retention capacity
improved in three cases. Intelligence and visuomotor co-ordination remained unchanged. None of
the patients showed any deterioration.
Two patients had reported for the testing at the end of one year, both showed considerable
improvement in attention and concentration, memory, immediate memory, retention and visual
recall. Intellectual function remained the same in these cases. One case showed improvement in
In Group IV with dementia, none of the patients deteriorated (though in their natural course they
usually tend to deteriorate) even at the end of one year while on observations and study.
In this study since a majority of the patients complained of poor immediate memory, difficulty in
retention and recall, these functions were quantitatively studied. The most affected functions at the
time of initial testing in all the three groups were attention, concentration and memory. Visuomotor
co-ordination was the least affected. None of the patients with dementia in Group IV deteriorated at
the end of one year. Of course, improvement is ordinarily not expected in this group, as they usually
None of the cases in any of the groups (including dementia, Group IV) showed even a slight degree
of deterioration in neuropsychological status after the administration of Geriforte. All the patients
showed a sense of well-being. Attention, concentration, immediate memory and retention improved
in all the first three groups. All the neuropsychological symptoms improved in Group III and one
patient in the peripheral type showed total relief from his complaints and improvement in
In conclusion, we might observe that Geriforte has shown good neuropsychological improvements
and a sense of well-being in all the patients when compared with the other drugs employed for the
same indications. It is also economical. There were no toxic or side effects. This preliminary study
has proved very stimulating, as the results are very encouraging. These conditions need closer study
particularly by the double blind method. Geriforte seems to have a definite place in the management
of neuropsychological complaints as listed above and is well worth a trial in order to provide relief
to patients in all the grades of neuromedical disorders.
1. Geriforte tablets 1 t.i.d. initially and 2 t.i.d. daily for one year were given to patients with
different neurological symptoms.
2. The patients were grouped into pure cerebral damage (26 patients), peripheral neurological
damage (4 patients), minimal symptoms (24 patients) and dementia group (16 patients).
3. The response to attention and concentration, memory, immediate memory, retention,
intelligence, visuomotor co-ordination and visual recall were studied.
4. All the patients showed good psychological improvement and a sense of well-being.
5. The dementia group did not show deterioration, even at the end of one year.
6. The drug is safe on prolonged use and there were no untoward side effects.